Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Cappuzzo

Showing results (201-210 of 275) with videos related to

Pageof 28
Sort By:
The Oncologist|April 19, 2019
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World PopulationLucio Crinò, Paolo Bidoli, Angelo Delmonte, et al.
Oncotarget|January 23, 2016
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNAMarzia Del Re, Marcello Tiseo, Paola Bordi, et al.
Cancers|October 17, 2020
Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES StudyMaria Pagano, Luca Giovanni Ceresoli, Paolo Andrea Zucali, et al.
Clinical Lung Cancer|December 20, 2018
Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR MutationsAntonio Passaro, Arsela Prelaj, Laura Bonanno, et al.
The Lancet. Oncology|May 25, 2019
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trialHoward West, Michael McCleod, Maen Hussein, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 26, 2021
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLCMark A Socinski, Makoto Nishio, Robert M Jotte, et al.
European Journal of Cancer (Oxford, England : 1990)|July 18, 2018
Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programmeFrancesco Grossi, Lucio Crinò, Antonio Logroscino, et al.
British Journal of Cancer|November 1, 2018
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutationsFrancesco Passiglia, Federico Cappuzzo, Oscar Alabiso, et al.
Journal for Immunotherapy of Cancer|November 23, 2019
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancerLorenza Landi, Federica D'Incà, Alain Gelibter, et al.
JAMA Oncology|June 4, 2026
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-AnalysisAlessandro Di Federico, Samuele Compagno, Francesco Mantuano, et al.
Pageof 28

Showing results (201-210 of 275) with videos related to

Sort By:
Pageof 28
The Oncologist|April 19, 2019
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World PopulationLucio Crinò, Paolo Bidoli, Angelo Delmonte, et al.
Oncotarget|January 23, 2016
Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNAMarzia Del Re, Marcello Tiseo, Paola Bordi, et al.
Cancers|October 17, 2020
Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES StudyMaria Pagano, Luca Giovanni Ceresoli, Paolo Andrea Zucali, et al.
Clinical Lung Cancer|December 20, 2018
Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR MutationsAntonio Passaro, Arsela Prelaj, Laura Bonanno, et al.
The Lancet. Oncology|May 25, 2019
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trialHoward West, Michael McCleod, Maen Hussein, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 26, 2021
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLCMark A Socinski, Makoto Nishio, Robert M Jotte, et al.
European Journal of Cancer (Oxford, England : 1990)|July 18, 2018
Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programmeFrancesco Grossi, Lucio Crinò, Antonio Logroscino, et al.
British Journal of Cancer|November 1, 2018
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutationsFrancesco Passiglia, Federico Cappuzzo, Oscar Alabiso, et al.
Journal for Immunotherapy of Cancer|November 23, 2019
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancerLorenza Landi, Federica D'Incà, Alain Gelibter, et al.
JAMA Oncology|June 4, 2026
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-AnalysisAlessandro Di Federico, Samuele Compagno, Francesco Mantuano, et al.
Pageof 28